|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||11.15 / 21.40|
Investors in Epizyme Inc. saw new options become available this week, for the August 2018 expiration.
Investors eyeing a purchase of Epizyme Inc. stock, but cautious about paying the going market price of $11.97/share, might benefit from considering selling puts among the alternative strategies at their disposal.
EZM8266 is the First of Three New Compounds to be Named as Part of Epizyme's Vision 2020
Data Highlights Company's Innovative Work in Translational Medicine to Identify Non-Hodgkin Lymphoma Patient Populations That May Derive Most Benefit
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
First presentation of pediatric dose escalation data in tazemetostat, showing favorable safety and tolerability with promising anti-tumor activity
Investors in Epizyme Inc. saw new options become available this week, for the May 2018 expiration.
Full Exercise of Underwriters' Option to Purchase Additional Shares
Summit Therapeutics and Epizyme are raising cash to fund new drug development.
GlaxoSmithKline could be among the suitors for United Therapeutics, the Evening Standard reported.
Eligible Patients to be Directed to Epizyme's Ongoing Phase 2 Clinical Trial of Tazemetostat in Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Sangamo Therapeutics, Epizyme and Revance were among the biotech stock movers in premarket trading on June 21.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.